Western study with sample size of 3.7 million people suggests Sputnik V best Covid-19 vaccine for preventing deaths
The comparative analysis of the performance of different jabs used in the central European country was unveiled, on Thursday, by the Russian Direct Investment Fund (RDIF), the sovereign wealth fund that bankrolled the jab's development.
“With 98% efficacy in preventing COVID-related mortality and 85.7% efficacy against coronavirus infection Sputnik V has demonstrated the best results among five vaccines (Sputnik V, Moderna, Pfizer-BioNTech, Sinopharm and AstraZeneca) administered in EU member state Hungary as part of an independent study based on data from 3.7 million people,” the CEO of the RDIF, Kirill Dmitriev, said in a statement on Thursday.
BREAKING: A unique 5-vaccine comparative nation-wide study of 3.7 million people in EU member Hungary shows that Sputnik offers best protection (98%) vs mortality from COVID. Also #SputnikV and Moderna lead other vaccines on efficacy vs COVID infection.👇https://t.co/JmaVFwrnZ4pic.twitter.com/SuuHjGnYOV— Sputnik V (@sputnikvaccine) November 25, 2021
While beating all the competitors in terms of protecting against coronavirus-related mortality, Sputnik V came second in Hungary in preventing the disease itself. The best result, in this category, was delivered by the US-made Moderna shot, which demonstrated 89% efficacy compared to 86% shown by Sputnik V.
The Russian-made shot also turned out to be “100% effective against COVID related deaths in individuals aged 16–44 years” according to the findings.
The new study comes a day after the RDIF presented the general public with an analysis of the long-term results of a mass-vaccination campaign in San Marino, which primarily used Sputnik V. Some 70% of the European microstate’s 34,000-strong population received the Russian-made jab.
The vaccine showed extremely high efficacy in San Marino, with “only 0.75 per 1,000 people” who were vaccinated with it ending up hospitalized. The jab also retained high efficacy over long periods, remaining some 80% effective against the disease from six to eight months after administering the second dose.
Sputnik V’s long-term efficacy “is much higher than officially published efficacy of mRNA vaccines,” the RDIF noted.
Think your friends would be interested? Share this story!